Renin-angiotensin-aldosterone system and progression of renal disease

Journal of the American Society of Nephrology

Volumn 17, Issue 11, 2006, Pages 2985-2991

  Rüster, Christiane ^a   Wolf, Gunter ^a,b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ADENYLATE CYCLASE; ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN[1-7]; CHYMASE; CONNECTIVE TISSUE GROWTH FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; RANTES; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RENIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

APOPTOSIS; AUTOREGULATION; DIABETIC NEPHROPATHY; DISEASE COURSE; ENDOCYTOSIS; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY DISEASE; KIDNEY FIBROSIS; MACROPHAGE; MALIGNANT HYPERTENSION; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTEMATIC REVIEW;

EID: 33750741932     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2006040356     Document Type: Review

References (49)

1. Remuzzi G, Benigni A, Remuzzi A: Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 116: 288-296, 2006
2. Campbell RC, Ruggeneti P, Remuzzi G: Halting the progression of chronic nephropathy. J Am Soc Nephrol 13: 190-195, 2002
3. Wolf G, Ritz E: Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications. Kidney Int 67: 799-812, 2005
4. Wolf G, Neilson EG: From converting enzyme inhibition to angiotensin II receptor blockade: New insights on angiotensin II receptor subtypes in the kidney. Exp Nephrol 4[Suppl 1]: 8-19, 1996
5. Huang XR, Chen WY, Truong LD, Lan HY: Chymase is upregulated in diabetic nephropathy: Implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 14: 1738-1747, 2003
6. Durvasula RV, Petermann AT, Hiromura K, Blonski M, Pippin J, Mundel P, Pichler R, Griffin S, Couser WG, Shankland SJ: Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 65: 30-39, 2004
7. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y, Penninger JM: Angiotensin- converting-enzyme 2 is an essential regular of heart function. Nature 417: 822-828, 2002
8. Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J, Cooper ME: Characterisation of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 41: 392-397, 2003
9. Danilczyk U, Penninger JM: Angiotensin-converting enzyme II in the heart and the kidney. Circ Res 98: 463-471, 2006
10. Wolf G, Mentzel S, Assmann KJ: Aminopeptidase A: A key enzyme in the intrarenal degradation of angiotensin II. Exp Nephrol 5: 364-369, 1997
11. Albiston AL, McDowall SG, Matsacos D, Sim P, Clune E, Mustafa T, Lee J, Mendelsohn FA, Simpson RJ, Connolly LM, Chai SY: Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem 276: 48623-48626, 2001
12. Wolf G, Butzmann U, Wenzel UO: The renin-angiotensin system and progression or renal disease: From hemodynamics to cell biology. Nephron Physiol 93: 3-13, 2003
13. Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, Friedlander G, Terzi F: Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: A new therapeutic approach. Nat Med 8: 867-874, 2005
14. Carey RM: Update on the role of the AT2 receptor. Curr Opin Nephrol Hypertens 14: 67-71, 2005
15. Ullian ME, Gelasco AK, Fitzgibbon WR, Beck CN, Morinelli TA: N-acetylcysteine decreases angiotensin II receptor binding in vascular smooth muscle cells. J Am Soc Nephrol 16: 2346-2353, 2005
16. Abdalla S, Lother H, Langer A, el Faramawy Y, Quitterer U: Factor XIIIA transglutaminase crosslinks ATI receptor dimers of monocytes at the onset of atherosclerosis. Cell 119: 343-354, 2004
17. Thway TM, Shlykov SG, Day MC, Sanborn BM, Gilstrap LC 3rd, Xia Y, Kellems RE: Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation. Circulation 110: 1612-1619, 2004
18. Dragun D, Muller DN, Brasen JH, Fritsche L, Nieminen-Kelha M, Dechend R, Kintscher U, Rudolph B, Hoebeke J, Eckert D, Mazak I, Plehm R, Schonemann C, Unger T, Budde K, Neumayer HH, Luft FC, Wallukat G: Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 352: 558-569, 2005
19. Jardine AG, Padmanabhan N, Connell JMC: Angiotensin converting enzyme gene polymorphisms and renal disease. Curr Opin Nephrol Hypertens 7: 259-264, 1998
20. Huang W, Gallois Y, Bouby N, Bruneval P, Heudes D, Belair MF, Krege JH, Meneton P, Marre M, Smithies O, Alhenc-Gelas F: Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proc Natl Acad Sci U S A 98: 13330-13334, 2001
21. Nishiyama A, Seth DM, Navar LG: Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension 39: 129-134, 2002
22. Beutler KT, Masilamani S, Turban S, Nielsen J, Brooks HL, Ageloff S, Fenton RA, Packer RK, Knepper MA: Long-term regulation of ENaC expression in kidney by angiotensin II. Hypertension 41: 1143-1150, 2003
23. Nishiyama A, Seth DM, Navar LG: Renal interstitial fluid I and angiotensin II concentrations during local angiotensin converting enzyme inhibition. J Am Soc Nephrol 13: 2207-2212, 2002
24. Zhuo JL, Imig JD, Hammond TG, Orengo S, Benes E, Navar LG: Ang II accumulation in rat renal endosomes during Ang II-induced hypertension. Role of AT1 receptor. Hypertension 39: 116-121, 2002
25. Wolf G: Link between angiotensin II and TGF-beta in the kidney. Miner Electrolyte Metab 24: 174-180, 1998
26. Sharma K, Cook A, Smith M, Valancius C, Inscho EW: TGF-beta impairs renal autoregulation via generation of ROS. Am J Physiol Renal Physiol 288: F1069-F1077, 2005
27. Brinkkoetter PT, Holtgrefe S, van der Woude FJ, Yard BA: Angiotensin II type 1-receptor mediated changes in heparan sulfate proteoglycans in human SV40 transformed podocytes. J Am Soc Nephrol 15: 33-40, 2004
28. Wolf G, Chen S, Ziyadeh FN: From the periphery of the glomerular capillary wall toward the center of disease. Podocyte injury comes of age in diabetic nephropathy. Diabetes 54: 1626-1634, 2005
29. Wolf G, Schroeder R, Stahl RAK: Angiotensin II induces hypoxia-inducible factor-1alpha in PC 12 cells through a posttranscriptional mechanism: Role of AT2- receptors. Am J Nephrol 24: 415-421, 2004
30. Chen S, Lee JS, Iglesias-de la Cruz MC, Kasama Y, Izquierdo-Lahuerta A, Wolf G, Ziyadeh FN: Angiotensin II stimulates alpha3(IV) collagen production in mouse podocytes via TGF-beta and VEGF signaling: Implications for diabetic nephropathy. Nephrol Dial Transplant 20: 1320-1328, 2005
31. Birn H, Christensen EI: Renal albumin absorption in physiology and pathology. Kidney Int 69: 440-449, 2006
32. Caruso-Neves C, Kwon SH, Guggino WB: Albumin endocytosis in proximal tubule cells is modulated by angiotensin II through an AT2 receptor-mediated protein kinase B activation. Proc Nat Acad Sci U S A 102: 17513-17518, 2005
33. Ruiz-Ortega M, Esteban V, Ruperez M, Sanchez-Lopez E, Rodriguez-Vita J, Carvajal G, Egido J: Renal and vascular hypertension-induced inflammation: Role of angiotensin II. Curr Opin Nephrol Hypertens 15: 159-166, 2006
34. Wolf G, Wenzel U, Burns KD, Harris RC, Stahl RA, Thaiss F: Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors. Kidney Int 61: 1986-1995, 2002
35. Zhan Y, Brown C, Maynard E, Anshelevich A, Ni W, Ho IC, Oettgen P: Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling. J Clin Invest 115: 2508-2516, 2005
36. Wolf G, Bondeva T, Bohlender J, Roger T, Thaiss F, Wenzel U: Angiotensin II upregulates Toll-like receptor 4 on mesangial cells. J Am Soc Nephrol 17: 1585-1593, 2006
37. Jankowski V, Vanholder R, van der Griet M, Henning L, Tolle M, Schonfelder G, Krakow A, Karadogan S, Gustavsson N, Gobom J, Webb J, Lehrach H, Giebing G, Schluter H, Hilgers KF, Zidek W, Jankowski J: Detection of angiotensin II in supernatants of stimulated mononuclear leukocytes by matrix-assisted laser desorption ionization time-of-flight/time-of-flight mass analysis. Hypertension 46: 591-597, 2005
38. Wolf G, Neilson EG: Angiotensin II induces cellular hypertrophy in cultured murine proximal tubular cells. Am J Physiol 259: F768-F777, 1990
39. Wolf G, Wenzel U: Angiotensin II and cell cycle regulation. Hypertension 43: 693-698, 2004
40. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, Noble NA, Border W: Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 69: 105-113, 2006
41. Rodriguez-Vita J, Sabchez-Lopez E, Esteban V, Ruperez M, Egido J, Ruiz-Ortega M: Angiotensin II activates the smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation 111: 2509-2517, 2005
42. Abrahamsen CT, Pullen MA, Schnackenberg CG, Grygielko ET, Edwards RM, Laping NJ, Brooks DP: Effects of angiotensins II and IV on blood pressure, renal function, and PAI-1 expression in the heart and kidney of the rat. Pharmacology 66: 26-30, 2002
43. Kalluri R, Neilson EG: Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112: 1776-1784, 2003
44. Matsumoto K, Morishita R, Tomita N, Moriguchi A, Komai N, Aoki M, Matsumoto K, Nakamura T, Higaki J, Ogihara T: Improvement of endothelial dysfunction by angiotensin II blockade accompanied by induction of vascular hepatocyte growth factor system in diabetic spontaneously hypertensive rats. Heart Vessels 18: 18-25, 2003
45. Peng H, Carretero OA, Vuljai N, Liao TD, Motivala A, Peterson EL, Rhaleb NE: Angiotensin-converring enzyme inhibitors. A new mechanism of action. Circulation 112: 2436-2445, 2005
46. Fleming I, Kohlstedt K, Busse R: The tissue renin-angiotensin system and intracellular signaling. Curr Opin Nephrol Hypertens 15: 8-13, 2006
47. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B, Kintscher U: Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 54: 3442-3452, 2005
48. Nishiyama A, Abe Y: Molecular mechanisms and therapeutic strategies of chronic renal injury: Renoprotective effects of aldosterone blockade. J Pharmacol Sci 100: 9-16, 2006
49. Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, Lindschau C, Dechend R, Viedt C, Pilz B, Haller H, Luft FC: Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation 109: 2792-2800, 2004